drugset / Trial / NCT05173441
Human COVID-19 Immunoglobulin (COVID-HIG) Therapy for COVID-19 Patients
Phase 2
Unknown
180 enrolled
Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd.
Beijing Tiantan Biological Products Co., Ltd. · collabChina National Biotec Group Company Limited · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A randomized, double-blind, placebo-controlled phase II exploratory clinical trial to evaluate the efficacy and safety of Human COVID-19 immunoglobulin (pH4) for intravenous injection (COVID-HIG) in the treatment of patients with COVID-19.
Timeline
- Start
- 2021-12-30
- Primary completion
- 2023-06-20
- Completion
- 2023-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Human COVID-19 immunoglobulin | Protein / enzyme biologic | — | Intravenous |